`
`Information Disclosure Statement
`by A1>1>licant
`(Use several sheets if necessa1y)
`
`(37 CFR § l.98(b))
`
`U.S. Depaitweut of Colll.Jllercc Attorney Docket No.
`Patent and Trademark Office
`43612-0002014
`Applicant
`Teva Pharmaceuticals International GmbH
`I G{~u; ;11 U1u1
`Filiug Date
`May 5, 2017
`
`Sheet _1_ of _1_
`I Applicatiou No.
`15/588,461
`
`Examiner Desig.
`Initial
`ID
`
`Document
`Number
`
`U.S. Patent Documents
`Publication
`Date
`
`Patentee
`
`Class Subclass
`
`Filing Date
`If A
`ro riate
`
`Forei n Patent Documents or Published Forei
`Examiner Desig.
`Document
`Publication
`Country or
`Number
`Date
`Patent Office
`Initial
`ID
`
`Ii cations
`Translation
`Yes
`No
`
`Class Subclass
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Examiner Desig.
`Initial
`ID
`
`Document
`Brody et al., "Aptamers as therapeutic and diagnostic agents," Reviews in Molecular Biotechnology
`74(1):5-13, March 2000
`Declaration of Dr. Jes Olesen Number 3 regarding EP1957106, dated June 12, 2017
`
`Declaration of Dr. Leonard Presta Number 2, regarding EP1957106, dated June 12, 2017
`Hershey et al., "Investigation of the species selectivity of a nonpeptide CGRP receptor antagonist
`using a novel pharmacodynamic assay," Regulatory Peptides 127(1):71-77, April 2005
`Van Wijngaarden et al, "Inhibitors of Ocular Neovascularization: Promises and Potential
`Problems," JAMA, American Medical Association 293(12):1509-151 3, March 2005
`
`1.
`
`2.
`
`3.
`
`4.
`
`5.
`
`Examiner Signature
`
`Date Considered
`
`EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with
`next communication to applicant.
`
`Substitute Disclosure Form
`
`